Pharma major Lupin Limited (Lupin) announced the launch of Potassium Chloride (KCl) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Lupin's Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC's Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately USD 90 million in the U.S. (IQVIA MAT September 2019).
Shares of LUPIN LTD. was last trading in BSE at Rs.744.9 as compared to the previous close of Rs. 742.25. The total number of shares traded during the day was 48789 in over 1320 trades.
The stock hit an intraday high of Rs. 759.35 and intraday low of 742.5. The net turnover during the day was Rs. 36657591.